Balaji Virassamy
Overview
Explore the profile of Balaji Virassamy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dixon-Douglas J, Virassamy B, Clarke K, Hun M, Luen S, Savas P, et al.
NPJ Breast Cancer
. 2024 Oct;
10(1):94.
PMID: 39433772
The role of adaptive immunity in long-term outcomes in early breast cancer is increasingly recognised. Standard (neo)adjuvant chemotherapy can have adverse effects on immune cells. We conducted a retrospective longitudinal...
2.
Harris M, Savas P, Virassamy B, OMalley M, Kay J, Mueller S, et al.
Nat Rev Cancer
. 2024 Jul;
24(8):554-577.
PMID: 38969810
The tumour immune microenvironment is shaped by the crosstalk between cancer cells, immune cells, fibroblasts, endothelial cells and other stromal components. Although the immune tumour microenvironment (TME) serves as a...
3.
Rayson V, Harris M, Savas P, Hun M, Virassamy B, Salgado R, et al.
Trends Cancer
. 2024 Mar;
10(6):490-506.
PMID: 38521654
Triple-negative breast cancers (TNBCs) exhibit heightened T cell infiltration, contributing to an enhanced response to immune checkpoint blockade (ICB) compared with other subtypes. An immune-rich immune microenvironment correlates with improved...
4.
Teo Z, OConnor M, Versaci S, Clarke K, Brown E, Percy L, et al.
NPJ Breast Cancer
. 2023 Aug;
9(1):68.
PMID: 37582853
Novel therapeutic strategies that can effectively combine with immunotherapies are needed in the treatment of triple-negative breast cancer (TNBC). We demonstrate that combined PARP and WEE1 inhibition are synergistic in...
5.
Li R, Sant S, Brown E, Caramia F, Nikolic B, Clarke K, et al.
J Natl Cancer Inst
. 2023 May;
115(7):805-814.
PMID: 37166471
Background: Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors have poor efficacy in patients with trastuzumab-resistant advanced HER2-positive breast cancer. Tucatinib is a potent, selective anti-HER2 tyrosine...
6.
Virassamy B, Caramia F, Savas P, Sant S, Wang J, Christo S, et al.
Cancer Cell
. 2023 Feb;
41(3):585-601.e8.
PMID: 36827978
CD8 tumor-infiltrating lymphocytes with a tissue-resident memory T (T) cell phenotype are associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, the relative contribution of CD8 T...
7.
Byrne A, Savas P, Sant S, Li R, Virassamy B, Luen S, et al.
Nat Rev Clin Oncol
. 2020 Mar;
17(6):341-348.
PMID: 32112054
The presence of tumour-infiltrating lymphocytes (TILs) is associated with favourable outcomes in patients with breast cancer as well as in those with other solid tumours. T cells make up a...
8.
Savas P, Virassamy B, Ye C, Salim A, Mintoff C, Caramia F, et al.
Nat Med
. 2018 Aug;
24(12):1941.
PMID: 30135555
In the version of this article originally published, the institution in affiliation 10 was missing. Affiliation 10 was originally listed as Department of Surgery, Royal Melbourne Hospital and Royal Womens'...
9.
Savas P, Virassamy B, Ye C, Salim A, Mintoff C, Caramia F, et al.
Nat Med
. 2018 Jun;
24(7):986-993.
PMID: 29942092
The quantity of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is a robust prognostic factor for improved patient survival, particularly in triple-negative and HER2-overexpressing BC subtypes. Although T cells are...
10.
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Teo Z, Versaci S, Dushyanthen S, Caramia F, Savas P, Mintoff C, et al.
Cancer Res
. 2017 Sep;
77(22):6340-6352.
PMID: 28947417
New treatments for triple-negative breast cancer (TNBC) are urgently needed. Despite there being little evidence of clinical activity as single-agent therapies, we show that dual blockade of PI3Kα and CDK4/6...